Semaglutide
Useful mainly for adults with type 2 diabetes and/or obesity (and overweight with cardiovascular risk) under a prescriber.
Prescription medication — not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with type 2 diabetes and/or obesity (and overweight with cardiovascular risk) under a prescriber
Common dosing range
Injectable: titrated to 1-2 mg weekly for diabetes, up to 2.4 mg weekly for weight management; oral: 7-14 mg daily
When to expect effects
Glucose lowering within weeks; substantial weight loss over months (peak around 60-68 weeks)
Watch out for
Boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma); risk of pancreatitis
What is it
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. It is available as a once-weekly subcutaneous injection (Ozempic, Wegovy) and a once-daily oral tablet (Rybelsus). It is FDA-approved for type 2 diabetes, for chronic weight management, and to reduce cardiovascular events in specific populations.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
type 2 diabetes glycemic control Strong Evidence | HbA1c reduction of roughly 1.0-1.8% versus placebo or active comparators | Adults with type 2 diabetes inadequately controlled on diet or other agents | Weeks |
chronic weight management in obesity Strong Evidence | About 15% mean body-weight reduction versus ~2.4% with placebo at 68 weeks (STEP 1) | Adults with obesity or overweight with a weight-related condition, without diabetes | Months (continues to ~60-68 weeks) |
cardiovascular event reduction Strong Evidence | About 20% relative reduction in major adverse cardiovascular events versus placebo (SELECT, in overweight/obesity without diabetes) | Adults with established cardiovascular disease, with or without diabetes | Months to years |
type 2 diabetes glycemic control
- Effect
- HbA1c reduction of roughly 1.0-1.8% versus placebo or active comparators
- Best fit
- Adults with type 2 diabetes inadequately controlled on diet or other agents
- Time
- Weeks
chronic weight management in obesity
- Effect
- About 15% mean body-weight reduction versus ~2.4% with placebo at 68 weeks (STEP 1)
- Best fit
- Adults with obesity or overweight with a weight-related condition, without diabetes
- Time
- Months (continues to ~60-68 weeks)
cardiovascular event reduction
- Effect
- About 20% relative reduction in major adverse cardiovascular events versus placebo (SELECT, in overweight/obesity without diabetes)
- Best fit
- Adults with established cardiovascular disease, with or without diabetes
- Time
- Months to years
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
type 2 diabetes glycemic control
Biomarker supportThe phase-3 SUSTAIN program randomized thousands of adults with type 2 diabetes and showed semaglutide lowered HbA1c by approximately 1.0-1.8% with accompanying weight loss, outperforming several active comparators including other GLP-1 agonists and insulin glargine on glycemic and weight endpoints. Hypoglycemia risk was low as a monotherapy because insulin secretion is glucose-dependent. These trials supported approval for type 2 diabetes.
Bottom line: Semaglutide produces large, reliable HbA1c reductions with weight loss in type 2 diabetes.
chronic weight management in obesity
Disease adjunctIn the phase-3 STEP 1 trial, adults without diabetes who received semaglutide 2.4 mg weekly with lifestyle intervention lost about 15% of body weight versus roughly 2.4% with placebo over 68 weeks, with nearly a third losing 20% or more. Companion STEP trials confirmed benefit across populations, including those with type 2 diabetes (with somewhat smaller loss). Weight is largely regained after discontinuation, underscoring chronic-disease management.
Bottom line: At the 2.4 mg dose, semaglutide produces clinically large, sustained weight loss as long as treatment continues.
cardiovascular event reduction
Disease adjunctThe SELECT trial randomized adults with established cardiovascular disease and overweight/obesity but without diabetes to semaglutide 2.4 mg or placebo and found about a 20% relative reduction in the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Earlier, the SUSTAIN-6 cardiovascular outcomes trial in type 2 diabetes showed reduced cardiovascular events. These outcome trials underpin the cardiovascular risk-reduction indication.
Bottom line: Semaglutide reduces major cardiovascular events in established cardiovascular disease, a benefit beyond glucose and weight.
How to take it
What to track
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Boxed warning: thyroid C-cell tumors, including medullary thyroid carcinoma, seen in rodents (human relevance unknown)
Acute pancreatitis
Gallbladder disease (cholelithiasis, cholecystitis)
Acute kidney injury from dehydration with severe GI symptoms
Diabetic retinopathy worsening in some patients
Severe hypoglycemia when combined with insulin or sulfonylureas
Reports of ileus and aspiration risk under anesthesia from delayed gastric emptying
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma
- People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with prior serious hypersensitivity to semaglutide
- People with a history of pancreatitis (use with caution)
- Pregnant individuals
Pregnancy & breastfeeding
Not recommended in pregnancy; discontinue at least 2 months before a planned pregnancy because of the long half-life.
Interactions
Additive glucose lowering raises hypoglycemia risk; doses of these often need reduction
Delayed gastric emptying can alter the rate/extent of absorption of co-administered oral drugs
Changed gastric emptying may affect absorption; monitor INR or drug levels
The strict fasting administration window for Rybelsus can conflict with levothyroxine timing and absorption
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
References by claim
type 2 diabetes glycemic control
chronic weight management in obesity
Rubino et al., 2021 — PMC (2021) link
Track Semaglutide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.